Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Namilumab (Primary) ; Prednisone (Primary)
- Indications Cardiomyopathies; Sarcoidosis
- Focus Adverse reactions
- Acronyms RESOLVE-Heart
- Sponsors Kinevant Sciences GmbH
- 13 Dec 2022 Status changed from recruiting to discontinued since sponsor business decision not related to safety.
- 15 Aug 2022 According to a Roivant Sciences media release, topline data is expected in the first half of calendar year 2024.
- 05 Aug 2022 Status changed from not yet recruiting to recruiting.